• 1
    Pieper JA, Lima H. Lidocaine. In Applied Pharmacokinetics. Principles of Therapeutic Drug Monitoring, edition 3rd edn, eds EvansWE, SchentagJJ, JuskoWJ. Vancouver, WA: Applied Therapeutics, Inc. 1992, chapter 21.
  • 2
    Bargetzi MJ, Aoyama T, Gonzales FJ, Meyer UA. Lidocaine metabolism in human liver microsomes by cytochrome P450 IIIA4. Clin Pharmacol Ther 1989; 46: 521527.
  • 3
    Pai MP, Graci DM, Amsden GW. Macrolide drug interactions: an update. Ann Pharmacother 2000; 34: 495513.
  • 4
    Westphal JF. Macrolide-induced clinically relevant drug interactions with cytochrome P-450 (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 2000; 50: 285295.
  • 5
    Isohanni MH, Neuvonen PJ, Palkama VJ, Olkkola KT. Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lidocaine. Eur J Clin Pharmacol 1998; 54: 561565.
  • 6
    Swart EL, Van Der Hoven B, Groeneveld ABJ, Touw DJ, Danhof M. Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers. Br J Clin Pharmacol 2002; 53: 133139.
  • 7
    Huet PM, Villeneuve JP. Determinants of drug disposition in patients with cirrhosis. Hepatology 1983; 6: 913918.
  • 8
    Lin JH, Lu AYH. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998; 35: 361390.
  • 9
    Shiffman ML, Luketic VA, Sanyal AJ, Thompson EB. Use of hepatic lidocaine metabolism to monitor patients with chronic liver disease. Ther Drug Monit 1996; 18: 372377.
  • 10
    Villeneuve LP, Thibeault MJ, Ampelas M et al. Drug disposition in patients with HBsAg-positive chronic liver disease. Dig Dis Sci 1987; 32: 710714.
  • 11
    Conn HO. A peek at the Child-Turcotte classification. Hepatology 1981; 6: 673676.
  • 12
    Phug RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646649.
  • 13
    Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP 3A. Annu Rev Pharmacol Toxicol 1998; 38: 389430.
  • 14
    Greenblatt DJ, Von Moltke LL, Harmatz JS et al. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin Pharmacol Ther 1998; 64: 278285.
  • 15
    O'Neal CL, Poklis A. Sensitive HPLC for simultaneous quantification of lidocaine and its metabolites monoethylglycinexylidide and glycinexylidide in serum. Clin Chem 1996; 42: 330331.
  • 16
    Wagner JG. Linear pharmacokinetic equations allowing direct calculation of many needed parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. J Pharmacokin Biopharm 1976; 4: 443467.
  • 17
    Wang JS, Backman JT, Taavitsainen P, Neuvonen PJ, Kivistö KT. Involvement of CYP 1A2 and CYP 3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos 2000; 28: 959965.
  • 18
    Keenaghan JB, Boyes RN. The tissue distribution, metabolism and excretion of lidocaine in rats, guinea pigs, dogs and man. J Pharmacol Exp Ther 1972; 180: 454463.
  • 19
    Hoyumpa AM, Schenker S. Major drug interactions: effect of liver disease, alcohol and malnutrition. Ann Rev Med 1982; 33: 113149.
  • 20
    Brower KLR, Dukes GE, Powell JR. Influence of liver function on drug disposition. In Applied Pharmacokinetics. Principles of Therapeutic Drug Monitoring, edition 3rd edn, eds EvansWE, SchentagJJ, JuskoWJ. Vancouver, WA: Applied Therapeutics, Inc., 1992, chapter 6.
  • 21
    Rossi JS, Schroder TJ, Vine WH et al. Monoethylglycinexylidide formation in assessing pediatric donor liver function. Ther Drug Monit 1992; 14: 452456.
  • 22
    Sotaniemi EA, Rautio A, Bäckstrom M, Arvela P, Pelkonen O. CYP 3A4 and CYP 2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney disease and epileptic patients. Br J Clin Pharmacol 1995; 39: 7176.
  • 23
    Reichel C, Skodra T, Nacke A, Spengler U, Sauerbruch T. The lignocaine metabolite (MEGX) liver function test and P-450 induction in humans. Br J Clin Pharmacol 1998; 46: 535539.
  • 24
    Orlando R, Palatini P. The effect of age on plasma MEGX concentrations. Br J Clin Pharmacol 1997; 44: 206208.
  • 25
    Barry M, Keelig PWN, Weir D, Feely J. Severity of cirrhosis and the relationship of α1-acid glycoprotein concentration to plasma protein binding of lidocaine. Clin Pharmacol Ther 1990; 47: 366370.